According to the Zhitong Finance app, hainan shuangcheng pharmaceuticals (002693.SZ) announced that the company's stock trading price deviated from the closing price for two consecutive trading days on October 16, 2024, and October 17, 2024, with a cumulative deviation exceeding 20%. According to relevant regulations of the Shenzhen Stock Exchange, this situation falls under abnormal stock trading fluctuations.

The company warns of risks: the company is planning a major asset restructuring. The company intends to purchase 100% of Ora's shares held by 25 trading parties such as Ola Investment and Win Aiming by issuing shares and paying cash, and plans to issue shares to raise matching funds from no more than 35 specific investors. As of the date of this announcement, the auditing and evaluation work of this transaction has not been completed, and the specific transaction price of this transaction has not been determined. This restructuring requires the necessary internal decision-making process and must be formally implemented after approval from the relevant regulatory authorities. There is uncertainty about the final successful implementation, so investors are advised to pay attention to subsequent announcements and be aware of investment risks.